CTNM Contineum Therapeutics, Inc.
Nasdaq · SEC CIK 1855175 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $1.86M 22 sales by 3 insiders
- Filings on record
- 63 since 2024-04-11, latest 2026-09-08 18:08
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Lorrain Daniel S. | CSO | — | $1.13M |
| Stengone Carmine N. | CEO, Pres, Dir | — | $401.4K |
| Watkins Tim | CMO, Head of Development | — | $322.6K |
Transactions 41
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-08 18:08 | 2026-09-08 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | M - OptEx | $1.01 | +2,500 | 19.7K | +15% | +$2,525 |
| DT | 2026-09-08 18:08 | 2026-09-08 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | S - Sale+OE | $16.46 | -2,500 | 17.2K | -13% | -$41.1K |
| DT | 2026-08-03 18:14 | 2026-08-03 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | M - OptEx | $1.01 | +2,500 | 19.7K | +15% | +$2,525 |
| DT | 2026-08-03 18:14 | 2026-08-03 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | S - Sale+OE | $16.01 | -2,500 | 17.2K | -13% | -$40.0K |
| DMT | 2026-07-10 17:20 | 2026-07-08+ | CTNM | Lorrain Daniel S. | CSO | M - OptEx | $1.01 | +1,040 | 135.2K | +0.8% | +$1,050 |
| DMT | 2026-07-10 17:20 | 2026-07-08+ | CTNM | Lorrain Daniel S. | CSO | S - Sale+OE | $16.00 | -1,040 | 135.2K | -0.8% | -$16.6K |
| DT | 2026-07-08 18:49 | 2026-07-08 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | M - OptEx | $1.01 | +2,500 | 19.7K | +15% | +$2,525 |
| DT | 2026-07-08 18:49 | 2026-07-08 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | S - Sale+OE | $16.00 | -2,500 | 17.2K | -13% | -$40.0K |
| DMT | 2026-07-02 17:47 | 2026-06-30+ | CTNM | Lorrain Daniel S. | CSO | M - OptEx | $1.01 | +33.0K | 143.6K | +30% | +$33.3K |
| DMT | 2026-07-02 17:47 | 2026-06-30+ | CTNM | Lorrain Daniel S. | CSO | S - Sale+OE | $15.99 | -37.2K | 135.2K | -22% | -$594.6K |
| DT | 2026-07-01 19:04 | 2026-06-30 | CTNM | Watkins Tim | CMO, Head of Development | M - OptEx | $4.50 | +10.8K | 19.8K | +121% | +$48.7K |
| DT | 2026-07-01 19:04 | 2026-06-30 | CTNM | Watkins Tim | CMO, Head of Development | S - Sale+OE | $16.02 | -10.8K | 8,961 | -55% | -$173.6K |
| DMT | 2026-07-01 19:04 | 2026-06-30 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | M - OptEx | $1.07 | +10.0K | 27.2K | +58% | +$10.7K |
| DT | 2026-07-01 19:04 | 2026-06-30 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | S - Sale+OE | $16.01 | -10.0K | 17.2K | -37% | -$160.1K |
| T | 2026-06-01 18:08 | 2026-06-01 | CTNM | Lorrain Daniel S. | CSO | S - Sale | $13.16 | -4,170 | 139.4K | -3% | -$54.9K |
| MT | 2026-05-01 17:42 | 2026-05-01 | CTNM | Lorrain Daniel S. | CSO | S - Sale | $13.12 | -4,170 | 143.5K | -3% | -$54.7K |
| T | 2026-04-06 17:43 | 2026-04-06 | CTNM | Lorrain Daniel S. | CSO | S - Sale | $13.43 | -4,170 | 147.7K | -3% | -$56.0K |
| D | 2026-03-02 | 2026-03-02 | CTNM | Watkins Tim | CMO, Head of Development | M - OptEx | $4.50 | +3,611 | 3,611 | New | +$16.2K |
| D | 2026-03-02 | 2026-03-02 | CTNM | Watkins Tim | CMO, Head of Development | S - Sale+OE | $15.02 | -3,611 | 0 | -100% | -$54.2K |
| 2026-03-02 | 2026-03-02 | CTNM | Lorrain Daniel S. | CSO | S - Sale | $15.01 | -4,170 | 151.9K | -3% | -$62.6K | |
| DM | 2026-02-26 | 2026-02-24+ | CTNM | Stengone Carmine N. | CEO, Pres, Dir | M - OptEx | $1.26 | +7,100 | 17.7K | +67% | +$8,946 |
| DM | 2026-02-26 | 2026-02-24+ | CTNM | Stengone Carmine N. | CEO, Pres, Dir | S - Sale+OE | $16.02 | -7,100 | 15.0K | -32% | -$113.7K |
| DM | 2026-02-26 | 2026-02-24+ | CTNM | Lorrain Daniel S. | CSO | M - OptEx | $1.01 | +8,124 | 159.9K | +5% | +$8,205 |
| DM | 2026-02-26 | 2026-02-24+ | CTNM | Lorrain Daniel S. | CSO | S - Sale+OE | $16.02 | -8,124 | 156.1K | -5% | -$130.2K |
| D | 2026-02-20 | 2026-02-19 | CTNM | Lorrain Daniel S. | CSO | S - Sale+OE | $16.00 | -100 | 156.1K | -0.1% | -$1,600 |
| D | 2026-02-20 | 2026-02-19 | CTNM | Lorrain Daniel S. | CSO | M - OptEx | $1.01 | +100 | 156.2K | +0.1% | +$101 |
| D | 2026-02-13 | 2026-02-11 | CTNM | Lorrain Daniel S. | CSO | M - OptEx | $1.01 | +400 | 156.5K | +0.3% | +$404 |
| D | 2026-02-13 | 2026-02-11 | CTNM | Lorrain Daniel S. | CSO | S - Sale+OE | $16.00 | -400 | 156.1K | -0.3% | -$6,400 |
| D | 2026-02-13 | 2026-02-11 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | M - OptEx | $1.26 | +400 | 15.4K | +3% | +$504 |
| D | 2026-02-13 | 2026-02-11 | CTNM | Stengone Carmine N. | CEO, Pres, Dir | S - Sale+OE | $16.00 | -400 | 15.0K | -3% | -$6,400 |
| M | 2026-02-05 | 2026-02-03 | CTNM | Lorrain Daniel S. | CSO | S - Sale | $14.94 | -4,170 | 156.1K | -3% | -$62.3K |
| DM | 2026-01-30 | 2026-01-28 | CTNM | Watkins Tim | CMO, Head of Development | S - Sale+OE | $14.18 | -3,611 | 0 | -100% | -$51.2K |
| D | 2026-01-30 | 2026-01-28 | CTNM | Watkins Tim | CMO, Head of Development | M - OptEx | $4.50 | +3,611 | 3,611 | New | +$16.2K |
| M | 2026-01-06 | 2026-01-05 | CTNM | Lorrain Daniel S. | CSO | S - Sale | $10.44 | -4,170 | 160.2K | -3% | -$43.5K |
| D | 2025-12-30 | 2025-12-29 | CTNM | Watkins Tim | CMO, Head of Development | S - Sale+OE | $12.06 | -3,611 | 0 | -100% | -$43.5K |
| D | 2025-12-30 | 2025-12-29 | CTNM | Watkins Tim | CMO, Head of Development | M - OptEx | $4.50 | +3,611 | 3,611 | New | +$16.2K |
| 2025-12-30 | 2025-12-23 | CTNM | Lorrain Daniel S. | CSO | S - Sale | $12.23 | -4,170 | 164.4K | -2% | -$51.0K | |
| 2024-11-27 | 2024-11-25 | CTNM | Lorrain Daniel S. | CSO | S - Sale | $16.02 | -1,010 | 168.6K | -0.6% | -$16.2K | |
| M | 2024-11-20 | 2024-11-18 | CTNM | Lorrain Daniel S. | CSO | S - Sale | $16.38 | -6,190 | 169.6K | -4% | -$101.4K |
| D | 2024-08-14 | 2024-08-13 | CTNM | Huhn Stephen L. | CMO, SVP, Clinical Dev | M - OptEx | $1.01 | +12.8K | 12.8K | New | +$12.9K |
| DMI | 2024-04-11 | 2024-04-09 | CTNM | Versant Vantage I, L.P. | 10% | C - Cnv Deriv | — | +542.6K | 2,531 | New | — |
Purchase Sale Sale after option exercise All abbreviations